http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102838677-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
| filingDate | 2010-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102838677-B |
| titleOfInvention | Recombinant erythropoietin and preparation method thereof |
| abstract | The invention relates to recombinant erythropoietin subjected to chemical modification and a preparation method thereof. Erythropoietin is recombined by adopting a genetic engineering technology, 2-ammonia-8-oxo-nonanoyl residue with chemical active ketone group is introduced into the erythropoietin, when covalent modification is conducted on the recombinant erythropoietin by polyethylene glycol, the polyethylene glycol and the 2-ammonia-8-oxo-nonanoyl residue are completely reacted in a specificity manner, the polyethylene glycol is not subjected to reaction with other amino acid residues, and the needed reaction conditions are temperate, so that the problems of poor selectivity and severe reaction conditions in the prior art are solved. A pharmacokinetic research result and a haematocrit measuring result of the recombinant erythropoietin being subjected to pegylation are superior to those of natural erythropoietin. |
| priorityDate | 2010-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 886.